Article Text
Abstract
Objectives—To assess the relationship between the approval of trials by a research ethics committee (REC) and the fact that informed consent from participants (ICP) was obtained, with the quality of study design and methods.
Design—Systematic review using a standardised checklist.
Main measures—Methodological and ethical issues of all trials published between 1993 and 1995 in the New England Journal of Medicine, the Lancet, the Journal of the American Medical Association and the British Medical Journal were studied. In addition, clinical trials conducted in Spain and published by at least one Spanish author during the same period in any other journal were also included.
Results—We studied the published articles of 767 trials and found the following indicators of lower methodological quality to be independent predictors for failure to disclose REC approval or ICP: absence of concealment of allocation, lack of justification for unblinded trials, not using a treatment for the patients in the control group, absent information on statistical methods, not including sample size estimation, not establishing the rules to stop the trial, and omitting the presentation of a baseline comparison of groups
Conclusion—Trials of higher methodological and scientific quality were more likely to provide information about their ethical aspects.
- Clinical trials
- informed consent
- research ethics committees
- research design
Statistics from Altmetric.com
Footnotes
-
Miguel Ruiz-Canela, BPharm, PhD, is Associate Professor in the Department of Biomedical Humanities,University of Navarre, Spain. Jokin de Irala-Estevez, MD, MPH, PhD, is Professor in the Department of Epidemiology and Public Health, University of Navarre. Miguel Ángel Martínez-González, MD, MPH, PhD, is Head of the Department of Epidemiology and Public Health, University of Navarre. Enrique Gómez-Gracia, MD, MPH, PhD, is Professor in the Department of Preventive Medicine and Public Health, University of Malaga, Spain. Joaquín Fernández-Crehuet, MD, MPH, PhD, is Head of the Department of Preventive Medicine and Public Health, University of Malaga, Spain. Address for readers' correspondence: Miguel Angel Martínez-Gonzalez, Epidemiología y Salud Pública, Irunlarrea s/n, Facultad de Medicina, Universidad de Navarra, 31080 Pamplona, Spain. Fax: (34)-48-425649; tel: (34)-48-425600; e-mail: mamartinez{at}unav.es
Read the full text or download the PDF:
Other content recommended for you
- Methodological quality and reporting of ethical requirements in phase III cancer trials
- Reporting of ethical requirements in phase III surgical trials
- The future of clinical trials: data sharing
- A cross-sectional examination of conflict-of-interest disclosures of physician-authors publishing in high-impact US medical journals
- Accessibility and transparency of editor conflicts of interest policy instruments in medical journals
- Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
- The Meaning of Author Order in Medical Research
- Scientific publications in respiratory journals from Chinese authors in various parts of North Asia: a 10-year survey of literature
- When I use a word . . . The ICMJE requirements and recommendations
- Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study